Spehlmann Martina-Elisabeth, Frey Norbert, Müller Oliver J
Klinik für Innere Medizin III (Kardiologie, Angiologie und Internistische Intensivmedizin), Universitätsklinikum Schleswig-Holstein, Arnold Heller-Str. 3, 24226, Kiel, Germany.
Herz. 2020 Nov;45(7):652-658. doi: 10.1007/s00059-020-04961-9.
Deep vein thrombosis and pulmonary artery embolism are common and serious concomitant diseases in patients with cancer. The prophylaxis and therapy of such venous thromboembolic events (VTE) in oncology have so far been achieved with low-molecular-weight heparins. An increasing number of studies show evidence of the use of direct oral anticoagulants. However, since none of the possible options were shown to have a clear advantage in all patients, the individual decision to use a drug should be made depending on its effectiveness in preventing VTE, the risk of bleeding, the nature of the cancer, the interactions with other medications, the route of administration, and finally the cost of treatment.
深静脉血栓形成和肺动脉栓塞是癌症患者常见且严重的伴随疾病。迄今为止，肿瘤学中此类静脉血栓栓塞事件（VTE）的预防和治疗一直使用低分子量肝素。越来越多的研究表明了直接口服抗凝剂的使用证据。然而，由于所有可能的选择在所有患者中均未显示出明显优势，因此应根据药物预防VTE的有效性、出血风险、癌症性质、与其他药物的相互作用、给药途径以及最终的治疗成本来做出使用药物的个体决策。
